2004
An analysis of tumor necrosis factor α gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection
Thio C, Goedert J, Mosbruger T, Vlahov D, Strathdee S, O'Brien S, Astemborski J, Thomas D. An analysis of tumor necrosis factor α gene polymorphisms and haplotypes with natural clearance of hepatitis C virus infection. Genes & Immunity 2004, 5: 294-300. PMID: 15071492, DOI: 10.1038/sj.gene.6364072.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionC virus infectionHuman leukocyte antigenHCV infectionSingle nucleotide polymorphismsVirus infectionBlack subjectsTumor Necrosis Factor-α Gene PolymorphismsNecrosis factor-α gene polymorphismsCytokine tumor necrosis factor alphaTNF single nucleotide polymorphismsTumor necrosis factor alphaRole of TNFFunction of TNFΑ gene polymorphismsNecrosis factor alphaCohort of individualsHCV outcomesHCV clearanceViral clearanceLeukocyte antigenViral persistenceFactor alphaImmune responseNatural clearanceMICA and recovery from hepatitis C virus and hepatitis B virus infections
Karacki P, Gao X, Thio C, Thomas D, Goedert J, Vlahov D, Kaslow R, Strathdee S, Hilgartner M, O'Brien S, Carrington M. MICA and recovery from hepatitis C virus and hepatitis B virus infections. Genes & Immunity 2004, 5: 261-266. PMID: 15029237, DOI: 10.1038/sj.gene.6364065.Peer-Reviewed Original ResearchConceptsHepatitis C virusHepatitis B virus infectionChronic hepatitis BB virus infectionHepatitis BC virusVirus infectionMICA polymorphismNatural killer cellsHBV infectionHCV infectionHepatitis CKiller cellsViral clearanceViral persistenceT cellsStudy populationMICA allelesSignificant associationInfectionFurther investigationVirusAssociationPersonsDifferential distributionHepatitis C incidence—a comparison between injection and noninjection drug users in New York City
Fuller C, Ompad D, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence—a comparison between injection and noninjection drug users in New York City. Journal Of Urban Health 2004, 81: 20-24. PMID: 15047780, PMCID: PMC3456148, DOI: 10.1093/jurban/jth084.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersNoninjection drug usersDrug usersHCV seropositiveRisk of HCVNew injection drug usersPerson-time analysisAnnual incidence rateHepatitis C incidenceAnnual incident rateHigh-risk practicesHCV incidenceHCV seroconvertersNon-IDUsHCV serologyHCV preventionC virusRisk factorsIncidence ratePrevention servicesOnset of injectionEarly preventionNew York CityRisk Survey
2002
HLA-Cw*04 and Hepatitis C Virus Persistence
Thio C, Gao X, Goedert J, Vlahov D, Nelson K, Hilgartner M, O'Brien S, Karacki P, Astemborski J, Carrington M, Thomas D. HLA-Cw*04 and Hepatitis C Virus Persistence. Journal Of Virology 2002, 76: 4792-4797. PMID: 11967296, PMCID: PMC136132, DOI: 10.1128/jvi.76.10.4792-4797.2002.Peer-Reviewed Original ResearchConceptsHuman leukocyte antigenHCV infectionViral persistenceAcute hepatitis C virus (HCV) infectionAssociation of HLAHepatitis C virus infectionHepatitis C virus (HCV) persistenceKiller immunoglobulin-like receptorsClass I human leukocyte antigenEarly host immune responseC virus infectionHCV RNA levelsNatural killer cellsImmunoglobulin-like receptorsCytolytic T cellsHost immune responsePolymorphic HLA genesHCV clearanceHCV persistenceKiller cellsViral clearanceLeukocyte antigenPx groupForeign antigensT cells
2001
Racial Differences in HLA Class II Associations with Hepatitis C Virus Outcomes
Thio C, Thomas D, Goedert J, Vlahov D, Nelson K, Hilgartner M, O’Brien S, Karacki P, Marti D, Astemborski J, Carrington M. Racial Differences in HLA Class II Associations with Hepatitis C Virus Outcomes. The Journal Of Infectious Diseases 2001, 184: 16-21. PMID: 11398104, DOI: 10.1086/321005.Peer-Reviewed Original ResearchConceptsHuman leukocyte antigenClass II associationsViral clearanceClass II HLA typingClass II human leukocyte antigenHepatitis C virus clearanceHLA class II associationsCD4 T cell responsesT cell responsesClass II allelesHepatitis C virus outcomeHCV clearanceLeukocyte antigenVirus clearanceViral persistenceHLA typingImmune responseHomogeneous cohortCell responsesWhite subjectsDiverse cohortCohortClearanceVaried cohortsBlack subjectsHuman Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies
Mao Q, Ray S, Laeyendecker O, Ticehurst J, Strathdee S, Vlahov D, Thomas D. Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal Of Virology 2001, 75: 3259-3267. PMID: 11238852, PMCID: PMC114119, DOI: 10.1128/jvi.75.7.3259-3267.2001.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV quasispeciesHypervariable region 1HIV seroconversionChronic hepatitis C virus (HCV) infectionE2 hypervariable region 1Hepatitis C virus infectionHuman immunodeficiency virus (HIV) seroconversionRapid HIV disease progressionHepatitis C virus quasispeciesHIV infection altersHIV-associated diseaseChronic HCV infectionC virus infectionHIV disease progressionHCV infectionHCV RNASerum levelsLiver diseaseImmunodeficiency virusDisease progressionRapid progressionVirus infectionNumber of subjectsHCV sequences
2000
The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors
Thomas D, Astemborski J, Rai R, Anania F, Schaeffer M, Galai N, Nolt K, Nelson K, Strathdee S, Johnson L, Laeyendecker O, Boitnott J, Wilson L, Vlahov D. The Natural History of Hepatitis C Virus Infection: Host, Viral, and Environmental Factors. JAMA 2000, 284: 450-456. PMID: 10904508, DOI: 10.1001/jama.284.4.450.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseInjection drug useHepatitis C virus infectionC virus infectionHuman immunodeficiency virusViral clearanceHCV infectionLiver diseaseDrug usePersistent viremiaVirus infectionCases of ESLDRisk of ESLDCommunity-based prospective cohort studyAntibody-positive test resultPresence of ascitesProspective cohort studyCause of deathUtilization of treatmentMajority of adultsSemiannual visitsCohort studyHCV RNAEsophageal varicesImmunodeficiency virusDeterminants of the Quantity of Hepatitis C Virus RNA
Thomas D, Astemborski J, Vlahov D, Strathdee S, Ray S, Nelson K, Galai N, Nolt K, Laeyendecker O, Todd J. Determinants of the Quantity of Hepatitis C Virus RNA. The Journal Of Infectious Diseases 2000, 181: 844-851. PMID: 10720503, DOI: 10.1086/315314.Peer-Reviewed Original ResearchConceptsHCV RNA levelsHepatitis C virus RNAHIV-negative personsC virus RNAHCV RNARNA levelsLower HCV RNA levelsSerum HCV RNA levelsHepatitis B infectionInjection drug useHuman immunodeficiency virusVirus RNAVirologic factorsB infectionHCV infectionImmunodeficiency virusNeedle sharingBlood levelsPositive personsDrug useYounger ageInfectionEquivalents/Additional researchPerson variabilityScreening for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Individuals
Thio C, Nolt K, Astemborski J, Vlahov D, Nelson K, Thomas D. Screening for Hepatitis C Virus in Human Immunodeficiency Virus-Infected Individuals. Journal Of Clinical Microbiology 2000, 38: 575-577. PMID: 10655348, PMCID: PMC86151, DOI: 10.1128/jcm.38.2.575-577.2000.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV RNANegative participantsHepatitis C virus antibody testHuman immunodeficiency virus-infected individualsHepatitis C virus screeningThird-generation enzyme immunoassayHIV-negative participantsVirus-infected individualsHepatitis C virusInjection drug usersThird-generation assaysCOBAS AMPLICOR systemFalse-negative testsThird-generation testsFalse-negative resultsAcute infectionHIV infectionImmunodeficiency virusC virusAntibody formationAntibody testHCVVirus screeningAmplicor system
1999
Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection
Villano S, Vlahov D, Nelson K, Cohn S, Thomas D. Persistence of viremia and the importance of long‐term follow‐up after acute hepatitis C infection. Hepatology 1999, 29: 908-914. PMID: 10051497, DOI: 10.1002/hep.510290311.Peer-Reviewed Original ResearchConceptsRecombinant immunoblot assayHCV RNAAcute infectionViral clearanceAcute hepatitis C virus (HCV) infectionAcute hepatitis C infectionHepatitis C virus infectionPersistence of viremiaAcute HCV infectionAcute hepatitis CC virus infectionHepatitis C infectionTime of seroconversionPeak viral titersHealth care providersSingle laboratory testIllicit drug useHCV seroconversionC infectionHCV infectionHepatitis CPersistent viremiaClinical featuresHCV subtypesPolymerase chain reactionA prospective, community‐based evaluation of liver enzymes in individuals with hepatitis C after drug use
Inglesby T, Rai R, Astemborski J, Gruskin L, Nelson K, Vlahov D, Thomas D. A prospective, community‐based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999, 29: 590-596. PMID: 9918940, DOI: 10.1002/hep.510290219.Peer-Reviewed Original ResearchConceptsSerum ALT levelsALT levelsALT valuesDrug usePrior illicit drug useSerum alanine transaminase levelsAlanine transaminase levelsNormal ALT valuesHepatitis C virusIllicit drug useImportant disease outcomesElevated ALTHepatitis CTransaminase levelsInitial visitLiver biopsyVisit variabilityC virusCommunity-based evaluationLiver enzymesDisease outcomeHCVPatientsMore visitsNatural history
1995
Seroepidemiology of Hepatitis B Virus in a Population of Injecting Drug Users
Levine O, Vlahov D, Koehler J, Cohn S, Spronk A, Nelson K. Seroepidemiology of Hepatitis B Virus in a Population of Injecting Drug Users. American Journal Of Epidemiology 1995, 142: 331-341. PMID: 7631637, DOI: 10.1093/oxfordjournals.aje.a117639.Peer-Reviewed Original ResearchConceptsDrug usersHBV seropositivityHBV seromarkersHepatitis B virus infectionDrug injecting equipmentHigh-risk sexual behaviorB virus infectionHuman immunodeficiency virusInjecting Drug UsersHepatitis B virusHepatitis C virusAfrican American ethnicityHBV transmissionParenteral transmissionHBV infectionImmunodeficiency virusInjecting equipmentSexual transmissionC virusB virusInjecting careerVirus infectionDrug useShooting galleriesStreet outreachCorrelates of Hepatitis C Virus Infections among Injection Drug Users
Thomas D, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson K. Correlates of Hepatitis C Virus Infections among Injection Drug Users. Medicine 1995, 74: 212-220. PMID: 7623656, DOI: 10.1097/00005792-199507000-00005.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis C virus infectionC virus infectionHuman immunodeficiency virusHCV infectionDrug usersVirus infectionMajority of HCVYears of injectingLong-term drug usersHCV RNASerologic evidenceImmunodeficiency virusBloodborne pathogensInjection drugsViral persistenceImmune responsePersistent infectionHigh riskHCVDrug useBiologic basisStudy participantsInfectionIllicit drugs
1993
Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland
Vlahov D, Nelson K, Quinn T, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. European Journal Of Epidemiology 1993, 9: 566-569. PMID: 8307145, DOI: 10.1007/bf00209538.Peer-Reviewed Original Research